Pharmacogenetics of autoimmune diseases: Research issues in the case of Multiple Sclerosis and the role of IFN-β
- 31 December 2005
- journal article
- review article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 25, 1-5
- https://doi.org/10.1016/j.jaut.2005.09.008
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- IL‐10 promoter haplotype influence on interferon treatment response in multiple sclerosisEuropean Journal of Neurology, 2005
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004
- Genomic Effects of IFN-β in Multiple Sclerosis PatientsThe Journal of Immunology, 2003
- Management of multiple sclerosis: current trials and future optionsCurrent Opinion in Neurology, 2003
- Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosisGenes & Immunity, 2003
- Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over timeBrain, 2002
- The interferon-α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factorsCurrent Opinion in Immunology, 2002
- IFN-β-1b Inhibits IL-12 Production in Peripheral Blood Mononuclear Cells in an IL-10-Dependent Mechanism: Relevance to IFN-β-1b Therapeutic Effects in Multiple SclerosisThe Journal of Immunology, 2000
- Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patientsJournal of Neuroimmunology, 1999
- Defining the clinical course of multiple sclerosisNeurology, 1996